More News

15 July 2023

Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases

11 July 2023

NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3

11 July 2023

Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT’s Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets

11 July 2023

Doer Biologics Announces License Agreement with BioNTech

1 July 2023

Baudax Bio Acquires TeraImmune, Inc.

1 July 2023

Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy

30 June 2023

Lilly to Acquire Sigilon Therapeutics

28 June 2023

Caeregen Therapeutics and Wacker Biotech Announce Collaboration Agreement to Produce the Regenerative Medicine Clinical Candidate CTR-107 (Noregen™) for Retinal Diseases

28 June 2023

NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)

24 June 2023

Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions

21 June 2023

FDA Grants Full Approval for BLINCYTO® (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children

21 June 2023

Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology

12 June 2023

Eccogene Raises CNY 180 Million in Series B Equity Financing, Propelling its Pipeline of Treatments for Metabolic Diseases

12 June 2023

Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share)

9 June 2023

Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases

6 June 2023

Oncoinvent Presents 15-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in Colorectal Cancer Patients at the 2023 ASCO Annual Meeting

1 June 2023

Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd

1 June 2023

LTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat Cancer and Autoimmune Diseases

25 May 2023

HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson’s Disease

25 May 2023

Novo Nordisk and Life Edit Therapeutics Establish Multi-Target Collaboration to Discover and Develop Gene Editing Therapies for Rare and Cardiometabolic Diseases

24 May 2023

Pyxis Oncology to Acquire Apexigen

24 May 2023

Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP/p300 Inhibitor

23 May 2023

Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

23 May 2023

AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million

18 May 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) launches Luzsana Biotechnology™ (Luzsana)

17 May 2023

Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease

15 May 2023

Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis English

10 May 2023

Amgen and TScan Therapeutics announce collaboration to identify novel targets in Crohn’s disease

10 May 2023

Sobi to Acquire CTI BioPharma

10 May 2023

Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

Nectin-4-Targeted Immunotherapy Pipeline Review

Report Package: Bispecific Antibodies

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

FcRn Inhibitors Pipeline Review

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review